Welcome to our dedicated page for WEST PHARMACEUTICAL SERVICES SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on WEST PHARMACEUTICAL SERVICES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into WEST PHARMACEUTICAL SERVICES's regulatory disclosures and financial reporting.
West Pharmaceutical Services uses its 2026 proxy to highlight solid 2025 performance and key governance items ahead of the May 4, 2026 virtual annual meeting. Net sales reached $3.1B, up 6.3%, with organic growth of 4.3%. Reported-diluted EPS was $6.79 and adjusted-diluted EPS was $7.29, up 8%, while operating cash flow was $755M and free cash flow $469M, up 70%.
The Board proposes re-electing eleven directors, an annual advisory Say‑on‑Pay vote, ratification of the auditor, and opposes a shareholder proposal for an independent Board chair. The company emphasizes majority‑independent Board oversight, strong risk and cybersecurity frameworks, long‑running dividend growth, and a pay program heavily tied to performance, which received over 94% support in the 2025 Say‑on‑Pay vote. The proxy also notes CEO Eric Green’s intention to retire once a successor is hired in the second half of 2026.
West Pharmaceutical Services, Inc. announced that Eric M. Green, its President, Chief Executive Officer and Chair of the Board, plans to retire from all three roles once a successor is hired to support a smooth leadership transition.
The Board has engaged a leading executive recruiting firm and expects the transition to occur in the second half of 2026. At the same time, the Company reaffirmed its previously issued 2026 financial guidance from its February 12, 2026 earnings release.
Green has led West as President and CEO since April 2015 and became Chair in May 2022. During his tenure, the Company more than doubled sales, achieved total shareholder return of approximately 350%, and generated $3.07 billion in net sales in fiscal 2025.
West Pharmaceutical Services reported that SVP, General Counsel and Corporate Secretary Norman D. Finch Jr. received equity awards. He was granted 1,285 restricted stock units and 3,057 stock options, each with an exercise right to buy common shares. Both the restricted stock units and options vest in four equal annual installments beginning on March 1, 2027.
Green Eric Mark reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services reported that President, CEO and Board Chair Eric Mark Green received new equity awards. On March 1, 2026, he was granted 6,986 restricted stock units, each representing a contingent right to receive one share of WST common stock.
On the same date, he was also granted 16,630 stock options to buy WST common stock. Both the restricted stock units and the stock options vest in four equal annual installments beginning on March 1, 2027, tying the awards to multi‑year service and performance at the company.
Favorite Annette F reported acquisition or exercise transactions in this Form 4 filing.
WEST PHARMACEUTICAL SERVICES INC executive Annette F. Favorite, Sr. VP & Chief HR Officer, reported equity awards rather than open-market trades. She received 720 restricted stock units, each representing one share of WST common stock, and 1,712 stock options, all held directly. Both the restricted stock units and options vest in four equal annual installments beginning on March 1, 2027.
West Pharmaceutical Services senior vice president Shane Alden Campbell reported equity compensation grants consisting of restricted stock units and stock options. He acquired 1,131 restricted stock units, each representing the right to receive one share of West common stock, and 2,691 stock options with a right to buy West shares.
Both the restricted stock units and the stock options vest in four equal annual installments beginning on March 1, 2027, meaning the awards become exercisable or deliverable over time rather than all at once. These are non-cash, equity-based compensation awards and do not reflect any open-market stock purchases or sales.
McMahon Robert W. reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services granted its SVP & Chief Financial Officer, Robert W. McMahon, two equity awards. He received 3,082 restricted stock units, each representing the right to one share of common stock, and options for 7,337 shares. Both awards vest in four equal annual installments beginning on March 1, 2027.
Poussot Rodolphe Jean reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services senior vice president of Strategy & Corporate Development Rodolphe Jean Poussot received equity awards on March 1, 2026. He was granted 437 restricted stock units, each representing one share of common stock, and stock options for 1,040 shares. Both awards vest in four equal annual installments beginning on March 1, 2027.
Winters Chad reported acquisition or exercise transactions in this Form 4 filing.
WEST PHARMACEUTICAL SERVICES INC executive Chad Winters, VP and Chief Accounting Officer, reported equity awards on restricted stock units and stock options. He received 340 restricted stock units and 808 stock options as grants, both described as derivative securities with no cash paid per unit in these awards.
Each restricted stock unit represents a contingent right to receive one share of WST common stock. Both the restricted stock units and the stock options vest in four equal annual installments beginning on March 1, 2027, creating a multi-year, performance- and service-linked compensation structure for this officer.
WEST PHARMACEUTICAL SERVICES INC senior vice president Rodolphe Jean Poussot reported equity compensation activity involving restricted stock units and common shares. On February 20, 2026, he exercised 383.382 restricted stock units, which converted into the same number of common shares at no cash cost.
Following this conversion, his directly held common stock position increased, then 129.545 shares of common stock were automatically withheld at $241.12 per share to cover tax obligations, leaving 561.235 common shares held directly after the transactions. Footnotes state that restricted stock units convert into common stock on a one-for-one basis and reference an earlier grant of 1,143 units vesting in three equal annual installments.